Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group

Authors

Katherine E. Warren, National Cancer Institute, Bethesda, MD
Tina Y. Poussaint, Children's Hospital, Boston, MA
Gilbert Vezina, George Washington UniversityFollow
Darren Hargrave, Great Ormond Street Hospital for Children, London
Roger J. Packer, George Washington UniversityFollow
Stewart Goldman, Lurie Children's Hospital of Chicago, Chicago, IL
Patrick Y. Wen, Dana-Farber Cancer Institute, Boston, MA
Ian F. Pollack, Children's Hospital of Pittsburgh, Pittsburgh, PA,
David Zurakowski, Children's Hospital, Boston, MA
Larry E. Kun, St. Jude Children's Research Hospital, Memphis, TN
Michael D. Prados, University of California - San Francisco
Stefan Rutkowski, University Medical Center, Hamburg-Eppendorf
Mark W. Kieran, Dana-Farber Children's Hospital Cancer Center, Boston, MA

Document Type

Journal Article

Publication Date

9-2013

Journal

Pediatric Blood and Cancer

Volume

Volume 60, Issue 9

Inclusive Pages

1397-1401

APA Citation

Warren, K. E., Poussaint, T. Y., Vezina, G., Hargrave, D., Packer, R. J., Goldman, S., . . . Kieran, M. W. (2013). Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatric Blood and Cancer, 60(9), 1397-1401.

Peer Reviewed

1